← FDA DRUG APPROVALS
FDA ANDA · ANDA090398
AMLODIPINE AND OLMESARTAN MEDOXOMIL
Sponsor: MATRIX LABS LTD
APPLICATION
ANDA090398
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
None (Tentative Approval)
Products
AMLODIPINE AND OLMESARTAN MEDOXOMILNone (Tentative Approval)
AMLODIPINE BESYLATE 10MG/20MG, OLMESARTAN MEDOXOMIL · TABLET · ORAL
AMLODIPINE AND OLMESARTAN MEDOXOMILNone (Tentative Approval)
AMLODIPINE BESYLATE 5MG/20MG, OLMESARTAN MEDOXOMIL · TABLET · ORAL
AMLODIPINE AND OLMESARTAN MEDOXOMILNone (Tentative Approval)
AMLODIPINE BESYLATE 10MG/40MG, OLMESARTAN MEDOXOMIL · TABLET · ORAL
AMLODIPINE AND OLMESARTAN MEDOXOMILNone (Tentative Approval)
AMLODIPINE BESYLATE 5MG/40MG, OLMESARTAN MEDOXOMIL · TABLET · ORAL
Approval history
2011-03-07OriginalTA
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.